Unity Biotechnology

Unity Biotechnology, Inc. was a publicly traded American biotechnology company that develops drugs that target senescent cells. The company ceased operations in 2025. Source

Category
Software
Headquarters
South San Francisco, United States

Unity Biotechnology across Glyph

Unity Biotechnology across Glyph: timeline

  1. Unity Biotechnology stockholders approve dissolution (Emerging)
  2. Unity Biotechnology cuts all staff after ASPIRE data (Emerging)
  3. Senolytic UBX1325 results for diabetic macular edema published (Emerging)

Sources